December 9, 2023

The U.S. Facilities for Medicare and Medicaid Providers has revised its coverage allowing a number of makes use of of amyloid positron emission tomography (PET) scans, a non-invasive mind scan essential for figuring out amyloid plaques, a telltale signal of Alzheimer’s. 

“Amyloid PET scans are a confirmed instrument and might be an necessary a part of Alzheimer’s prognosis and therapy,” Maria Carrillo, chief science officer of the Alzheimer’s Affiliation, stated in an announcement.

Associated: Is There A Blood Take a look at for Alzheimer’s? Progress Underway, However Not Fairly Prepared

This shift is important because it aligns with the eligibility standards for newly developed Alzheimer’s medicine.

Amyloid PET scans have been beforehand restricted to a one-time use and primarily out there for scientific trial functions. Nonetheless, this modification opens the door for a extra intensive and accessible prognosis of Alzheimer’s, paving the best way for earlier, extra correct detection and figuring out therapy eligibility.

This transfer advantages sufferers in search of entry to Alzheimer’s medicine, together with Eisai Co Ltd ESALY/Biogen Inc’s BIIB Leqembi, together with Eli Lilly And Co’s LLY experimental drug, donanemab. 

These medicine give attention to eradicating beta-amyloid, a protein related to the development of Alzheimer’s, from the mind.

Moreover, this coverage change ensures that people might be eligible for presidency reimbursement for medicine like Leqembi and others by confirming the presence of amyloid within the mind. This affirmation is important and is now extra accessible with out invasive cerebrospinal fluid assessments, resembling lumbar punctures.

Citing RBC Capital Markets, an analyst Reuters reported that the change clarifies reimbursement for PET scans.

“Whereas it should possible take some months for the MACs to ascertain their very own reimbursement phrases, PET scans have been one of many key preliminary bottlenecks for Leqembi uptake,” the analyst stated.

Disclaimer: This content material was partially produced with the assistance of AI instruments and was reviewed and printed by Benzinga editors.

Supply Hyperlink :